Tag - TLSI

Developments

TriSalus launches trial evaluating pressure-enabled drug delivery in liver tumors

TriSalus Life Sciences (NASDAQ: TLSI) has initiated patient enrollment for its PREDICTT clinical trial designed to evaluate its novel Pressure-Enabled Drug Delivery (PEDD) approach in patients with primary or metastatic...

May 5, 2026

Feature

TriSalus developing novel therapeutic solutions for liver and pancreatic tumors

TriSalus Life Sciences (NASDAQ:TLSI) is addressing the mechanical and biologic barriers within the tumor microenvironment (TME) that make it challenging to successfully treat liver and pancreatic tumors.

January 9, 2024

Tag - TLSI

TriSalus launches trial evaluating pressure-enabled drug delivery in liver tumors

TriSalus developing novel therapeutic solutions for liver and pancreatic tumors

Subscribe